IceCure Medical Ltd.
ICCM Healthcare Medical Devices
IceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 2,068.2%, free cash flow grew 3.88% and total debt fell 64.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ICCM
IceCure Medical Ltd. (ICCM) EV/Sales
As of 16 October 2026, IceCure Medical Ltd. (ICCM) trades at a EV/Sales of −3.4×. Over the past ten years it has ranged from −3.5× (October 2026) to 1,428× (July 2021); the current reading is higher than 0% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.7× | (40.51%) |
| FY2024 | 16.4× | (96.38%) |
| FY2023 | 452× | 47.29% |
| FY2022 | 307× | (55.56%) |
| FY2021 | 691× | 248.29% |
| FY2020 | 198× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 5.2× | (77.10%) |
| Mar 2025 | 22.9× | 23.87% |
| Mar 2024 | 18.5× | (94.48%) |
| Sep 2023 | 335× | (2.46%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. | −3.4× |
| IVF INVO Fertility, Inc compare | −0.3× |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)